Severe spontaneous vertebral fractures after denosumab discontinuation: three case reports

wbldb

Aubry-Rozier, B.¹; Gonzalez-Rodriguez, E.¹; Stoll, D.¹; Lamy, O.¹

Severe spontaneous vertebral fractures after denosumab discontinuation: three case reports

Osteoporos Int. May 2016;27(5):1923-1925

©2015 International Osteoporosis Foundation and National Osteoporosis Foundation

Affiliations

¹Center of Bone Diseases, Bone and Joint Department, Lausanne University Hospital, Av. Pierre-Decker 4, 1011 Lausanne, Switzerland
Abstract and keywords

Osteoporosis treatments are usually given for a limited period of time in order to balance benefits and risks. We report three cases of postmenopausal women without any previous fragility fracture who presented severe spontaneous vertebral fractures after denosumab discontinuation. We think that the occurrence of these fractures could be explained by the severe rebound effect observed after denosumab discontinuation and that a consensus regarding the end of treatment with denosumab has to be defined.

Keywords: Denosumab discontinuation; Osteoporotic fracture; Osteoporotic treatment duration
Links

DOI: 10.1007/s00198-015-3380-y

PubMed: 26510845

WoS: 000374564800027
History

Received: 2015-08-14

Accepted: 2015-10-20

Online: 2015-10-28

Cited Works (5)

Year	Entry
2012	Black DM, Reid IR, Boonen S, Bucci-Rechtweg C, Cauley JA, Cosman F, Cummings SR, Hue TF, Lippuner K, Lakatos P, Leung PC, Man Z, Martinez RLM, Tan M, Ruzycky ME, Su G, Eastell R. The effect of 3 versus 6 years of Zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res. February 2012;27(2):243-254.
2006	Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA, Satterfield S, Wallace RB, Bauer DC, Palermo L, Wehren LE, Lombardi A, Santora AC, Cummings SR; FLEX Research Group. Effects of continuing or stopping alendronate after 5 years of treatment: the fracture intervention trial long-term extension (FLEX): a randomized trial. JAMA. December 27, 2006;296(24):2927-2938.
2011	Bone HG, Bolognese MA, Yuen CK, Kendler DL, Miller PD, Yang Y-C, Grazette L, San Martin J, Gallagher JC. Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J Clin Endocrinol Metab. April 2011;96(4):972-980.
2005	Prince R, Sipos A, Hossain A, Syversen U, Ish-Shalom S, Marcinowska E, Halse J, Lindsay R, Dalsky GP, Mitlak BH. Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment. J Bone Miner Res. September 2005;20(9):1507-1513.
2015	Papapoulos S, Lippuner K, Roux C, Lin CJF, Kendler DL, Lewiecki EM, Brandi ML, Czerwiński E, Franek E, Lakatos P, Mautalen C, Minisola S, Reginster JY, Jensen S, Daizadeh NS, Wang A, Gavin M, Libanati C, Wagman RB, Bone HG. The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM extension study. Osteoporos Int. December 2015;26(12):2773-2783.

Cited By (16)

Year	Entry
2017	Compston J, Cooper A, Cooper C, Gittoes N, Gregson C, Harvey N, Hope S, Kanis JA, McCloskey EV, Poole KES, Reid DM, Selby P, Thompson F, Thurston A, Vine N; The National Osteoporosis Guideline Group (NOGG). UK clinical guideline for the prevention and treatment of osteoporosis. Arch Osteoporos. December 2017;12(1):1-24.
2017	Tsourdi E, Langdahl B, Cohen-Solal M, Aubry-Rozier B, Eriksen EF, Guañabens N, Obermayer-Pietsch B, Ralston SH, Eastell R, Zillikens MC. Discontinuation of denosumab therapy for osteoporosis: a systematic review and position statement by ECTS. Bone. December 2017;105:11-17.
2020	Tripto-Shkolnik L, Fund N, Rouach V, Chodick G, Shalev V, Goldshtein I. Fracture incidence after denosumab discontinuation: real-world data from a large healthcare provider. Bone. January 2020;130:115150.
2021	Everts-Graber J, Reichenbach S, Gahl B, Ziswiler H, Studer U, Lehmann T. Risk factors for vertebral fractures and bone loss after denosumab discontinuation: a real-world observational study. Bone. March 2021;144:115830.
2022	Chai RC, McDonald MM. Visualisation of tumour cells in bone in vivo at single-cell resolution. Bone. May 2022;158:116113.
2022	Takegahara N, Kim H, Choi Y. RANKL biology. Bone. June 2022;159:116353.
2023	Cruchelow KR, Peter ME, Chakrabarti A, Gipson HM, Gregory WT, DeClercq J, Choi L, Tanner SB. Denosumab treatment lapses, discontinuation, and off-treatment fracture risk: a retrospective study of patients with osteoporosis in a real-world clinical setting. Bone. December 2023;177:116925.
2017	Reid IR, Horne AM, Mihov B, Gamble GD. Bone loss after denosumab: only partial protection with zoledronate. Calcif Tiss Int. October 2017;101(4):371-374.
2017	Anastasilakis AD, Polyzos SA, Makras P, Aubry-Rozier B, Kaouri S, Lamy O. Clinical features of 24 patients with rebound-associated vertebral fractures after denosumab discontinuation: systematic review and additional cases. J Bone Miner Res. June 2017;32(6):1291-1296.
2017	Tsai JN, Nishiyama KK, Lin D, Yuan A, Lee H, Bouxsein ML, Leder BZ. Effects of denosumab and teriparatide transitions on bone microarchitecture and estimated strength: the DATA-Switch HR-pQCT study. J Bone Miner Res. October 2017;32(10):2001-2009.
2018	Cummings SR, Ferrari S, Eastell R, Gilchrist N, Jensen J-EB, McClung M, Roux C, Törring O, Valter I, Wang AT, Brown JP. Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension. J Bone Miner Res. February 2018;33(2):190-198.
2020	Nyström A, Kiritopoulos D, Ullmark G, Sörensen J, Petrén‐Mallmin M, Milbrink J, Hailer NP, Mallmin H. Denosumab prevents early periprosthetic bone loss after uncemented total hip arthroplasty: results from a randomized placebo‐controlled clinical trial. J Bone Miner Res. February 2020;35(2):239-247.
2020	Everts‐Graber J, Reichenbach S, Ziswiler HR, Studer U, Lehmann T. A single infusion of zoledronate in postmenopausal women following denosumab discontinuation results in partial conservation of bone mass gains. J Bone Miner Res. July 2020;35(7):1207-1215.
2017	Bone HG, Wagman RB, Brandi ML, Brown JP, Chapurlat R, Cummings SR, Czerwiński E, Fahrleitner-Pammer A, Kendler DL, Lippuner K, Reginster J-Y, Roux C, Malouf J, Bradley MN, Daizadeh NS, Wang A, Dakin P, Pannacciulli N, Dempster DW, Papapoulos S. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol. July 2017;5(7):513-523.
2017	McClung MR, Wagman RB, Miller PD, Wang A, Lewiecki EM. Observations following discontinuation of long-term denosumab therapy. Osteoporos Int. May 2017;28(5):1723-1732.
2019	Fleps I. Assessing the Risk of Hip Fracture: Subject-Specific Dynamic Models for the Simulation of Sideways Fall Impact [PhD thesis]. Swiss Federal Institute of Technology Zürich; 2019.